Home Blog of Signal Transduction GPCR & G Protein CXCR

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

CXCR

Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics

430 views | Dec 31 2023

The upregulation of CXCR4 in activated B-cell-like DLBCL, associated with poorer prognosis, suggests CXCR4 as a potential therapeutic target, warranting further investigation and potential clinical trials for DLBCL treatment. [Read the Full Post]

CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation

420 views | Aug 20 2023

The study demonstrates that treatment with the CXCR3 antagonist AMG487 can effectively alleviate inflammation and pelvic pain in a mouse model of experimental autoimmune prostatitis (EAP), suggesting its potential as a therapeutic agent for the prevention and treatment of chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). [Read the Full Post]

[Roles of the CXCR1/CXCL8 axis in abnormal proliferation of bile duct epithelial cells in primary biliary cholangitis]

528 views | Aug 17 2023

The study concludes that the CXCR1/CXCL8 axis plays a role in the abnormal proliferation of bile duct epithelial cells in primary biliary cholangitis (PBC) through the activation of NF-κB and ERK pathways. [Read the Full Post]

Reparixin improves survival in critically ill and transplant patients: A meta-analysis

531 views | Aug 16 2023

Reparixin, an anti-inflammatory drug inhibiting interleukin 8 (IL-8) activity, was found to improve survival in critically ill or transplant patients, including both COVID-19 and non-COVID-19 patients, without increasing the risk of infection, according to a meta-analysis of nine randomized controlled trials. [Read the Full Post]

Senescent Human Pancreatic Stellate Cells Secrete CXCR2 Agonist CXCLs to Promote Proliferation and Migration of Human Pancreatic Cancer AsPC-1 and MIAPaCa-2 Cell Lines

457 views | Aug 07 2023

Senescent pancreatic stellate cells (PSCs) and their secreted chemokines, such as CXCLs, play a significant role in promoting the proliferation and migration of pancreatic cancer cells, suggesting their potential as therapeutic targets for pancreatic cancer treatment. [Read the Full Post]

Educational level-dependent melanoma awareness in a high-risk population in Switzerland

550 views | Aug 07 2023

The study revealed that melanoma patients had a higher tendency to use a higher sun protection factor (SPF) compared to at-risk patients, emphasizing the significance of UV protection in melanoma prevention. [Read the Full Post]

Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients

654 views | Jul 13 2023

The retrospective analysis suggests that chemo-mobilization with etoposide, cytarabine, and pegfilgrastim is a highly effective and tolerable strategy for mobilizing hematopoietic stem cells in poorly mobilizing patients with multiple myeloma (MM) or lymphoma. [Read the Full Post]

AMD3100-mediated CXCR4 inhibition impairs development of primary lymphoma of the central nervous system

801 views | Jul 13 2023

The inhibition of CXCR4-CXCL12 interactions by AMD3100 in primary lymphoma of the central nervous system (PCNSL) downregulates CD200 expression in lymphoma cells, leading to increased microglial activation, impaired lymphoma cell invasion, and reduced tumor size, suggesting the potential therapeutic utility of AMD3100 in PCNSL. [Read the Full Post]

Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity

495 views | Jun 20 2023

This study demonstrates that inhibiting the CXCL1-CXCR2 pathway through trans-tympanic administration of SB225002 or CXCR2 siRNA protects against cisplatin-induced hearing loss, preserves hair cell integrity, and reduces the expression of inflammatory mediators associated with ototoxicity. [Read the Full Post]

Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors

1592 views | Feb 07 2019

CXCL12 competition binding studies were proven to be highly valuable as an initial screening assay and indicative for the pharmacological and functional profile of competitive CXCR4 antagonists, which will help the design of new potent CXCR4 inhibitors. [Read the Full Post]